[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3060908T3 - Diagnosticering og behandling af autoimmune sygdomme - Google Patents

Diagnosticering og behandling af autoimmune sygdomme Download PDF

Info

Publication number
DK3060908T3
DK3060908T3 DK14855002.3T DK14855002T DK3060908T3 DK 3060908 T3 DK3060908 T3 DK 3060908T3 DK 14855002 T DK14855002 T DK 14855002T DK 3060908 T3 DK3060908 T3 DK 3060908T3
Authority
DK
Denmark
Prior art keywords
diagnosis
treatment
autoimmune diseases
autoimmune
diseases
Prior art date
Application number
DK14855002.3T
Other languages
English (en)
Inventor
Daniel J Sexton
Burt Adelman
Andrew Nixon
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of DK3060908T3 publication Critical patent/DK3060908T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Rehabilitation Therapy (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14855002.3T 2013-10-21 2014-10-17 Diagnosticering og behandling af autoimmune sygdomme DK3060908T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361893542P 2013-10-21 2013-10-21
PCT/US2014/061242 WO2015061182A1 (en) 2013-10-21 2014-10-17 Diagnosis and treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
DK3060908T3 true DK3060908T3 (da) 2021-05-25

Family

ID=52993412

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14855002.3T DK3060908T3 (da) 2013-10-21 2014-10-17 Diagnosticering og behandling af autoimmune sygdomme

Country Status (14)

Country Link
US (3) US10101344B2 (da)
EP (2) EP3060908B1 (da)
JP (3) JP6657098B2 (da)
KR (3) KR102665705B1 (da)
CN (2) CN110658337B (da)
AU (3) AU2014340449B2 (da)
BR (1) BR112016008975B1 (da)
CA (1) CA2927695C (da)
DK (1) DK3060908T3 (da)
ES (1) ES2873204T3 (da)
IL (4) IL293948A (da)
PL (1) PL3060908T3 (da)
PT (1) PT3060908T (da)
WO (1) WO2015061182A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897336C (en) 2013-01-20 2023-10-17 Dyax Corp. Evaluation and treatment of pkal-mediated disorders
KR102432826B1 (ko) 2013-10-21 2022-08-16 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
DK3060908T3 (da) 2013-10-21 2021-05-25 Dyax Corp Diagnosticering og behandling af autoimmune sygdomme
MX2018004763A (es) * 2015-10-19 2018-09-06 Dyax Corp Inmunoensayo para detectar quininogeno escindido de alto peso molecular.
AU2017325983B2 (en) * 2016-09-16 2023-12-07 Takeda Pharmaceutical Company Limited Protein biomarkers for diseases associated with the contact activation system
KR200490846Y1 (ko) 2019-04-09 2020-01-13 이대호 각도조절 브라켓
KR20230050770A (ko) 2021-10-08 2023-04-17 김경민 발로 열 수 있는 반려동물 울타리
WO2024003617A2 (en) * 2022-06-30 2024-01-04 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
KR960009766B1 (ko) 1986-09-10 1996-07-24 니혼 소오끼 세이야꾸 가부시기가이샤 생리 활성물질 측정법
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) * 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
AU2548992A (en) 1991-08-13 1993-03-16 Temple University - Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT739355E (pt) 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
WO1997014028A2 (en) 1995-10-11 1997-04-17 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
JP4106888B2 (ja) 2001-09-19 2008-06-25 カシオ計算機株式会社 液晶表示装置および携帯端末装置
US8148171B2 (en) 2001-10-09 2012-04-03 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
ATE528014T1 (de) 2002-06-07 2011-10-15 Dyax Corp Polypeptid mit modifizierten kunitz domains
AU2003245676A1 (en) 2002-06-24 2004-01-06 Cornell Research Foundation, Inc. Exhaustive selection or rna aptamers against complex targets
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
WO2004039487A1 (en) 2002-11-01 2004-05-13 Mcmaster University Multicomponent protein microarrays
US7329742B2 (en) 2003-09-04 2008-02-12 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
EP1700912B1 (en) 2003-11-22 2014-10-29 Techno Medica Co., Ltd. Method of detecting target molecule by using aptamer
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
RU2007117752A (ru) 2004-10-13 2008-11-20 Аблинкс Н.В. (Be) Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера
MX363423B (es) 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
SI1981519T1 (en) 2005-12-29 2018-05-31 Dyax Corp. INHIBITION PROTEAZE
WO2008016883A2 (en) 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2089712A4 (en) * 2006-11-22 2010-09-22 Life Technologies Corp BIOMARKERS OF AUTOIMMUNE DISEASES
US20080255766A1 (en) 2007-02-16 2008-10-16 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of sickle cell
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2009053050A1 (en) 2007-10-22 2009-04-30 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
WO2010004962A1 (ja) * 2008-07-07 2010-01-14 日本臓器製薬株式会社 線維筋痛症の検査法
AU2009320061A1 (en) 2008-11-03 2010-06-03 Merck Sharp & Dohme Corp. Inflammatory bowel disease biomarkers and related methods of treatment
US20110318359A1 (en) 2008-12-02 2011-12-29 Feener Edward P Method for reducing blood pressure using inhibitors of plasma kallikrein
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) * 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JP5299179B2 (ja) * 2009-09-02 2013-09-25 株式会社リコー 画像形成装置
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EA201200917A1 (ru) 2009-12-18 2012-12-28 Эктивсайт Фармасьютикалз, Инк. Пролекарства ингибиторов плазменного калликреина
US9206123B2 (en) * 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
PT3459564T (pt) 2010-01-06 2022-01-31 Takeda Pharmaceuticals Co Proteínas de ligação à calicreína plasmática
WO2012009447A2 (en) * 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
BR112013013414B1 (pt) 2010-12-02 2023-01-10 Becton, Dickinson And Company Dispositivo para coleta e estabilização de sangue ou de um componente do mesmo, usos do dito dispositivo e kit compreendendo o mesmo
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
EP3320922A1 (en) 2011-06-10 2018-05-16 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US9187749B2 (en) * 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
CA2897336C (en) 2013-01-20 2023-10-17 Dyax Corp. Evaluation and treatment of pkal-mediated disorders
MX2015009914A (es) 2013-02-01 2015-09-25 Becton Dickinson Co Dispositivos de recogida de sangre que contienen aditivos de inhibicion de la via de contacto.
KR102432826B1 (ko) 2013-10-21 2022-08-16 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
DK3060908T3 (da) 2013-10-21 2021-05-25 Dyax Corp Diagnosticering og behandling af autoimmune sygdomme
KR20240049627A (ko) 2014-01-21 2024-04-16 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
MX2018004763A (es) 2015-10-19 2018-09-06 Dyax Corp Inmunoensayo para detectar quininogeno escindido de alto peso molecular.
CA3008621A1 (en) 2015-12-15 2017-06-22 Dyax Corp. Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
WO2021154992A1 (en) * 2020-01-28 2021-08-05 Orgenesis Inc. Process and system for acellular therapy

Also Published As

Publication number Publication date
EP3060908A1 (en) 2016-08-31
IL245206B (en) 2020-06-30
IL245206A0 (en) 2016-06-30
IL284969A (en) 2021-08-31
KR102665705B1 (ko) 2024-05-14
BR112016008975A2 (pt) 2017-09-19
AU2020200423B2 (en) 2022-03-31
AU2022204649A1 (en) 2022-07-21
AU2014340449A1 (en) 2016-06-02
WO2015061182A1 (en) 2015-04-30
EP3060908B1 (en) 2021-02-24
CN105874332B (zh) 2019-11-12
EP3060908A4 (en) 2017-03-22
ES2873204T3 (es) 2021-11-03
KR102485948B1 (ko) 2023-01-06
JP6657098B2 (ja) 2020-03-04
IL275368B (en) 2021-08-31
CA2927695A1 (en) 2015-04-30
KR20160089368A (ko) 2016-07-27
AU2014340449B2 (en) 2019-10-31
IL293948A (en) 2022-08-01
CN105874332A (zh) 2016-08-17
AU2020200423A1 (en) 2020-02-13
US10101344B2 (en) 2018-10-16
KR102295623B1 (ko) 2021-08-31
JP2017500584A (ja) 2017-01-05
US20160252533A1 (en) 2016-09-01
JP7157089B2 (ja) 2022-10-19
US20200371120A1 (en) 2020-11-26
AU2022204649B2 (en) 2024-08-22
JP2020091296A (ja) 2020-06-11
US12061206B2 (en) 2024-08-13
IL275368A (en) 2020-07-30
KR20230010003A (ko) 2023-01-17
US20190120862A1 (en) 2019-04-25
PL3060908T3 (pl) 2021-10-25
JP2022191343A (ja) 2022-12-27
IL284969B (en) 2022-07-01
CA2927695C (en) 2022-03-01
KR20210107182A (ko) 2021-08-31
CN110658337A (zh) 2020-01-07
CN110658337B (zh) 2023-06-16
JP7541560B2 (ja) 2024-08-28
US10648990B2 (en) 2020-05-12
BR112016008975B1 (pt) 2023-02-28
PT3060908T (pt) 2021-05-27
EP3913364A1 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
DK2968208T3 (da) Behandling af kataplexi
DK2882441T3 (da) Behandling af immunrelaterede og inflammatoriske sygdomme
DK3024497T3 (da) Fremgangsmåder og præparater til behandling af hjernesygdomme
DK3041926T3 (da) Indretning til in-vitro-modellering af in-vivo-væv af organer
DK3202305T3 (da) Engangsendoskop og system
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
DK3021838T3 (da) Behandling af fedme
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3347016T3 (da) Diagnosticering og behandling af angstlidelse
DK3060908T3 (da) Diagnosticering og behandling af autoimmune sygdomme
DK3003117T3 (da) Videolaryngoskop og laryngoskopindføringsdel
DK2964255T3 (da) Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
DK3238707T3 (da) Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
DK3044315T3 (da) Nukleinsyrer og fremgangsmåder til behandling af pompes sygdom
DK3470018T3 (da) Kryokonservering af levedygtige menneskehudssubstitutter
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte
DK3237621T3 (da) Varianter af human alpha-galactosidase
DK3057979T3 (da) Proteiner med diagnostiske og terapeutiske anvendelser
DK3598971T3 (da) Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin
DK2991620T3 (da) Kombinationer af antipyrin og benzocain til behandling af sygdomme forbundet med en kranienerve
DK3041831T3 (da) Alfa-te-saltformer: sammensætninger og anvendelser til behandling af sygdom
DK2964248T3 (da) Behandling af og profylakse for stråledermatitis
HK1220127A1 (zh) 自身免疫性疾病的治療
DK2976101T3 (da) Behandlingsfremgangsmåde